We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-20.94%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$322M
AUM Growth
-$149M
Cap. Flow
-$24.6M
Cap. Flow %
-7.63%
Top 10 Hldgs %
58.84%
Holding
48
New
9
Increased
13
Reduced
15
Closed
3

Top Buys

Rank Stock Value
1
BCYC
Bicycle Therapeutics
BCYC
+$8.17M
2
EWTX icon
Edgewise Therapeutics
EWTX
+$3.9M
3
MRSN
Mersana Therapeutics
MRSN
+$3.32M
4
PRQR icon
ProQR Therapeutics
PRQR
+$3.31M
5
MASS icon
908 Devices
MASS
+$2.86M

Top Sells

Rank Stock Value
1
CLDX icon
Celldex Therapeutics
CLDX
+$20.7M
2
SMLR
Semler Scientific
SMLR
+$6.84M
3
CYTK icon
Cytokinetics
CYTK
+$6.16M
4
STRO icon
Sutro Biopharma
STRO
+$5.61M
5
BBIO icon
BridgeBio Pharma
BBIO
+$5.47M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
26
MacroGenics
MGNX
$260M
$3.32M 1.03%
376,400
-85,600
-19% -$945K
VSTM icon
27
Verastem
VSTM
$668M
$3.28M 1.02%
193,750
– –
FULC icon
28
Fulcrum Therapeutics
FULC
$294M
$3.22M 1%
+136,000
New +$1.92M
MASS icon
29
908 Devices
MASS
$459M
$3.16M 0.98%
+166,406
New +$2.86M
EWTX icon
30
Edgewise Therapeutics
EWTX
$4.8B
$2.94M 0.91%
+303,000
New +$3.9M
MRSN
31
DELISTED
Mersana Therapeutics
MRSN
$2.83M 0.88%
+28,400
New +$3.32M
HYPR icon
32
Hyperfine
HYPR
$89.7M
$2.7M 0.84%
763,075
– –
SYBX
33
DELISTED
Synlogic
SYBX
$2.36M 0.73%
65,613
+8,946
+16% +$279K
PRQR icon
34
ProQR Therapeutics
PRQR
$327M
$2.19M 0.68%
2,425,000
+989,490
+69% +$3.31M
NGNE icon
35
Neurogene
NGNE
$758M
$1.49M 0.46%
39,500
-12,865
-25% -$751K
AVEO
36
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$1.34M 0.42%
240,000
-23,400
-9% -$96.4K
LENZ
37
LENZ Therapeutics
LENZ
$151M
$1.3M 0.4%
+36,500
New +$2.28M
LQDA icon
38
Liquidia Corp
LQDA
$6.26B
$1.28M 0.4%
178,800
+162,000
+964% +$1.02M
MODD icon
39
Modular Medical
MODD
$29.4M
$1.17M 0.36%
+8,870
New +$1.04M
AVTX icon
40
Avalo Therapeutics
AVTX
$1.08B
$1.05M 0.33%
505
-2
-0.4% -$5.02K
NCNA
41
NuCana
NCNA
$6.12M
$878K 0.27%
176
-62
-26% -$678K
RPTX
42
DELISTED
Repare Therapeutics
RPTX
$793K 0.25%
+55,678
New +$826K
STRO icon
43
Sutro Biopharma
STRO
$353M
$740K 0.23%
8,998
-59,002
-87% -$5.61M
DERM icon
44
Journey Medical
DERM
$213M
$324K 0.1%
+67,000
New +$334K
BLRX
45
BioLineRX
BLRX
$12.1M
$29K 0.01%
417
– –
BBIO icon
46
BridgeBio Pharma
BBIO
$15.4B
– –
-328,100
Closed -$5.47M
LITS
47
Lite Strategy Inc
LITS
$34M
– –
-65,750
Closed -$3.51M
SRRA
48
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-165,778
Closed -$3.6M
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2022 Portfolio in Review

As of Q1 2022, Opaleye Management held 48 positions worth $322M, down 32% from $471M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Opaleye Management withdrew a net $24.6M in Q1 2022, closing 3 positions and reducing 15 holdings. Its most notable exit was BridgeBio Pharma, an estimated $5.47M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Opaleye Management opened a new position in Bicycle Therapeutics worth $7.68M.

  • Opaleye Management's largest Q1 2022 buy was Bicycle Therapeutics: 175,000 shares worth $7.68M.
  • Opaleye Management added most to ProQR Therapeutics in Q1 2022, an estimated $3.31M increase.
  • Opaleye Management's biggest Q1 2022 reduction was Celldex Therapeutics, cutting an estimated $20.7M.
  • Opaleye Management fully exited BridgeBio Pharma in Q1 2022, selling an estimated $5.47M.
  • Opaleye Management's ten largest holdings make up 59% of its $322M portfolio in Q1 2022.
  • Opaleye Management opened 9 new positions and closed 3 in Q1 2022.
  • Opaleye Management's portfolio value fell 32% quarter-over-quarter to $322M.

Based on Opaleye Management's 13F filing for Q1 2022, filed 16 May 2022.